Research To Practice | Oncology Videos

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 2: Later-Line Treatment for Advanced NETs — Pamela Kunz, MD CME information and select publications

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 1: First-Line Therapy for Advanced Neuroendocrine Tumors (NETs) — Simron Singh, MD, MPH CME information and select publications

Featuring perspectives from Dr Pamela Kunz and Dr Simron Singh , including the following topics: Introduction (0:00) Overview (4:04) Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors (NETs) (27:07) Multitarget Tyrosine Kinase Inhibitors for the Treatment of NETs (39:37) Other New Advances in the Management of NETs (50:29) CME information and select publications

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 1: HER2-Targeted Strategies for HER2-Positive Gastroesophageal and Colorectal Cancers — John Strickler, MD CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr John Strickler , including the following topics: Introduction: Back-to-School Special (0:00) Biomarker Assays in Advanced Gastrointestinal (GI) Cancers (10:12) Sequencing of Treatment for HER2-Positive GI Cancers (28:37) Toxicities Associated with Anti-HER2 Treatment (48:32) Novel Agents and Strategies for HER2-Positive GI Cancers (58:10) CM...

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 2: Emerging Role of HER2-Targeted Therapy in Advanced Biliary Tract Cancers (BTCs) — Tanios Bekaii-Saab, MD CME information and select publications

Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics: Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00) First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira  (32:48) Later-...

Featuring perspectives from Dr Mrinal Gounder, including the following topics: Epidemiology, classification, genetics and diagnosis of sarcomas (0:00) Contemporary medical treatment of sarcomas (5:29) Targeted therapy for the treatment of sarcomas (9:01) Incidence, pathophysiology, classifications and clinical manifestations of liposarcomas (16:27) Current clinical treatment of dedifferentiated li...

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics: Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00) Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42) Other Targets for ADC Therapy in mBC — Prof Schmid (44:59) CME information and select publications

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 2: Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhD CME information and select publications

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 1: Expanding Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) Management — Sara M Tolaney, MD, MPH CME information and select publications

Featuring a slide presentation and related discussion from Dr Michiel van der Heijden , including the following topics: Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00) Principal findings from the Phase III CheckMate 901 substudy o...

Featuring an interview with Dr Michiel van der Heijden, including the following topics: Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00) Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adverse events (3:15) Activity of anti-PD1/PD-L1 and a...

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility o...

Featuring an interview with Prof Giuseppe Curigliano, including the following topics: Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00) Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02) Selection and sequencing of treatment for patients with HR-positive, HER2-negative dis...

Featuring an interview with Dr Angeles Alvarez Secord, including the following topics: Front-line management of ovarian cancer (0:00) Management of relapsed/refractory ovarian cancer (20:06) Management of microsatellite instability-high/mismatch repair-deficient endometrial cancer (23:20) Management of microsatellite stable/mismatch repair-proficient endometrial cancer (33:13) Targeted therapy for...

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Professor Solange Peters, MD, PhD CME information and select publications

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Professor Ben Solomon, MBBS, PhD CME information and select publications

Featuring perspectives from Prof Solange Peters and Prof Ben Solomon, including the following topics: Introduction (0:00) Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Prof Peters (9:17) Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Prof Solomon (33:01) CME infor...

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Case: A woman in her late 40s who received treatment for triple-negative breast cancer develops lung metastases 2 years later (0:00) Clinical trials investigating TROP2-targeting antibody-drug conjugates (13:28) Identifying and targeting HER2 in HER2 low-expressing disease (21:17) Case: A woman in her early 50s who rece...

Featuring perspectives from Dr Melissa Johnson, Dr Ticiana Leal and Dr Manish Patel , including the following topics: Introduction: Two Faces of Lung Cancer Research (0:00) B7-H3-Targeted Antibody-Drug Conjugates for Lung Cancer — Dr Patel (16:14) Potential Role of Tumor Treating Fields in the Management of Metastatic Non-Small Cell Lung Cancer — Dr Leal (32:36) Emerging Role of Bispecific T-Cell...

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates for MM — Jesús G Berdeja, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Thomas Martin, MD CME information and select publications

Featuring perspectives from Dr Jesús G Berdeja and Dr Thomas Martin, including the following topics: Introduction: Real-World Regulatory Issues in Multiple Myeloma (MM) (0:00) Newly Diagnosed MM (14:30) Novel Agents for Relapsed/Refractory MM (24:58) Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies (44:28) CME information and select publications

Featuring perspectives from Dr Evan J Lipson , including the following topics: Introduction: Johns Hopkins University (0:00) Metastatic Melanoma (8:21) Nonmetastatic Melanoma and Other Skin Cancers (34:20) CME information and select publications